Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011) September 12, 2022
Himalaya Therapeutics Announces Submission In Mainland China Of IND Applications For Its CAB-AXL-ADC To Treat Sarcomas And NSCLC, Its CAB-ROR2-ADC To Treat Melanoma And NSCLC October 4, 2021